Drug lookup
Drug reference

Lomitapide

Statin · Hyperlipidaemia

StatinHyperlipidaemia
CDSCO approved
EXCRETION
not curated
INTERACTIONS
12 major
incl. contraindicated
PREGNANCY
not curated
Top interactionssee all 12
  • LopinavirContraindicatedTextbookG&G 14e · p742
  • AbacavirSevereDatabaseDDInter
  • AbemaciclibSevereDatabaseDDInter
  • AbirateroneSevereDatabaseDDInter

Mechanism

Lomitapide inhibits microsomal triglyceride transfer protein (MTP), an enzyme essential for the lipidation and assembly of apolipoprotein B-containing lipoproteins (VLDL in the liver and chylomicrons in the intestine). By blocking MTP, it prevents VLDL secretion from hepatocytes, reducing circulating LDL cholesterol by 40-50% — even in patients with homozygous familial hypercholesterolemia who have no functional LDL receptors. Its use is restricted to homozygous FH because MTP inhibition causes hepatic triglyceride accumulation and steatosis, requiring regular liver monitoring and a strict low-fat diet.

Indications

Homozygous familial hypercholesterolaemiapatients who have not responded adequately to diet and other appropriate measuresAdjunct to diet for lowering LDL-C, total cholesterol, apo B, and non–HDL-C in patients with HoFH

Dosing

Adult
Initially 40 mg once daily, then increased if necessary up to 80 mg once daily, adjusted at intervals of at least 4 weeks, dose to be taken at night
Max dose
80 mg once daily

Pharmacokinetics

Metabolism
Metabolized by CYP3A4

Contraindications

  • Inhibitors of CYP3A4
  • Women of childbearing potential (unless negative pregnancy test and effective contraception are used due to embryotoxicity)

Side effects

Common
Significant diarrheaVomitingAbdominal pain
Serious
  • Hepatotoxicity
  • Liver steatosis
  • Elevations in ALT or AST greater than three times the upper limit of normal

Drug interactions

Lopinavir
Contraindicated
Textbook

Increased risk of lomitapide adverse effects, particularly hepatotoxicity.

Lomitapide is contraindicated with inhibitors of CYP3A4.

Source: G&G 14e · p742

Abacavir
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Abemaciclib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Abiraterone
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Acarbose
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Acitretin
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Afatinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Aldesleukin
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Alectinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Ambrisentan
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Aminosalicylic Acid
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Amiodarone
Severe
Database

Increased plasma concentrations of statins and their active metabolites, leading to an increased risk of myopathy and rhabdomyolysis.

Consider using pravastatin, fluvastatin, or rosuvastatin, as they are not extensively metabolized by CYP3A4. Carefully weigh the benefits against the risk of myopathy.

Source: DDInter

Related guidelines

Other Statin drugs

Ask House about Lomitapide

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-10 · House clinical team